AbbVie Beats And Effectively Absorbs Its IPR&D Charge, But Skyrizi's Slowdown Tests A Stock Priced At Its Highs

AbbVie (NYSE: ABBV) delivered another clean quarter. Adjusted EPS of $3.82 topped the $3.74 consensus by 2.1%, and revenue of $17.404 billion edged past the $17.37 billion estimate by 0.2%. Revenue grew 10.3% year over year. Adjusted earnings grew 105.4%, and GAAP EPS jumped to $2.37 from $0.10. That earnings growth figure needs context. The year-ago quarter absorbed $2.7 billion of acquired IPR&D and milestones expense, a $1.50 per-share hit, compared with just $0.11 this quarter. The adjusted tax rate also fell to 13.6% from 24.5%. The triple-digit growth rate therefore reflects an easy comparison more than a step change in profitability. The more telling signals are steady double-digit top-line growth and another guidance raise. The central tension is that AbbVie's growth engine is broadening just as its largest product decelerates, and the stock already trades as if the good news is locked in.

On the surface, the quarter even looks like a slight miss against AbbVie's own plan. Adjusted EPS came in below the original $3.84-$3.88 third-quarter guidance. The shortfall is entirely the $0.11 IPR&D charge; excluding it, earnings landed about 7 cents above the midpoint. Full-year guidance shows the same pattern, and the framing deserves care. AbbVie says it raised 2026 adjusted EPS guidance to $13.95-$13.99 from $13.76-$13.96. That prior range is the second-quarter outlook of $13.87-$14.07 reduced for the third-quarter IPR&D charge. Measured against the range investors heard in July, the midpoint is essentially unchanged and the range narrowed to just four cents. In practice, AbbVie absorbed the $0.11 charge through stronger operations, an underlying raise rather than a headline one. Revenue guidance rose again to $67.8 billion, up $800 million since the initial outlook. Adjusted gross margin improved to 85.1% from 84.7% in the second quarter and 83.6% in the first.

Beneath the headline, the mix is shifting. Skyrizi still grew 22.9% to $5.776 billion, and its full-year guide was raised a third time, to $21.8 billion. Its growth rate, however, has slid every quarter: 31.9%, then 29.2%, 24%, and now 22.9%, as oral IL-23 and IBD competition build. Rinvoq is moving the other way. Its growth accelerated from 20.2% to 23.7% to 24.3%, with guidance lifted to $10.3 billion. Neuroscience was the standout, up 19.5%, with its guide raised $300 million to $13.0 billion. Vraylar, Qulipta, Ubrelvy, and Vyalev all contributed. Oncology turned slightly positive at +0.9% after declining 2.4% in the second quarter, although Imbruvica fell 26.1% and its guide was cut to $2.1 billion. Aesthetics remains the weak link. The segment declined 1.8% operationally, worse than the second quarter's -0.9% and well below the first quarter's +5.1%. Juvederm fell 11.8%. The $5.0 billion segment guide survived only because a Botox Cosmetic raise offset cuts elsewhere.

The pipeline news was unusually dense, and management's tone was more emphatic. Management argued that the Street under-models several multibillion-dollar assets. Developments included:

• FDA approval of Juvmo (tavapadon) in Parkinson's, with early demand running ahead of plan;
• approval of subcutaneous Skyrizi induction in Crohn's, along with relaxed tuberculosis-testing language, which management expects to support share gains in the first half of 2027;
• an etentamig BLA, with approval expected in 2027;
• positive Phase 3 results for Epkinly in frontline DLBCL, lutikizumab in hidradenitis suppurativa, and Qulipta in menstrual migraine;
• the close of the Apogee acquisition;
• a district court ruling that Botox is ineligible for IRA price negotiation;
• a 5.2% dividend increase.

Bears still have legitimate ammunition. The Botox ruling faces a government appeal. U.S. approval of TrenibotE slipped to mid-2027 after a manufacturing-related complete response letter. Juvmo's ramp is back-end loaded because broad Medicare coverage is not expected until 2028. Apogee adds leverage and interest expense. The full-year adjusted operating margin guide has drifted from 48.5% to 46.7%; management attributes this to acquired IPR&D rather than core erosion.

The market setup is more demanding than the modest beat implies. Shares have climbed 15.1% since the open after the July report, to $290.79. The stock sits about 23% above its 200-day moving average and just 0.6% below a 52-week high of $292.67, set the day before results. It rallied roughly 20% off its August low, entering the print at the top of its inter-earnings range. Investor sentiment improved modestly, from 0.18 to 0.26, still positive but hardly euphoric. The Earnings Whispers trend signals are uniformly positive, consistent with the steady price advance. With the stock already priced for strength, a 2% beat and an underlying raise may be hard to treat as fresh news.

The bottom line is that AbbVie's diversification is working. Rinvoq, neuroscience, and a stabilizing oncology franchise are increasingly carrying growth that once depended on Skyrizi. The pipeline also gained several tangible 2027 catalysts. Still, Skyrizi's steady deceleration, the shrinking aesthetics business, and a guide that narrowed more than it expanded leave less room for upside surprise. With the stock at its highs, investors are now paying for that execution to continue, not discovering it.

Read our earnings preview for AbbVie Inc.: https://www.earningswhispers.com/article/ABBV/21268

This earnings review was originally published on Earnings Whispers.

This article is for informational purposes only and is not investment advice. Earnings Whispers and its staff may hold positions in the securities mentioned. It is AI-assisted, based on proprietary Earnings Whispers data and company reports, and edited by Earnings Whispers staff.